Inquiry

* Please note that all of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Ulixertinib

Cat. No.: IBDI-435293

Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC50 of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line.

Size (Solution): 10 mM * 1 mL in DMSO

Size (Solid + Solvent): 10 mM * 1 mL ready for reconstitution

Size (Solid):

Product Details

Target ERK
Molecular Weight 433.33
Appearance Solid
Synonyms BVD-523, VRT752271
SMILES O=C(C1=CC(C2=CC(NC(C)C)=NC=C2Cl)=CN1)N[[email protected]@H](C3=CC=CC(Cl)=C3)CO
Purity 99.95%

Storage & Handling

Shipping Room temperature in continental US. May vary elsewhere.
Storage Powder: -20°C/3 years; 4°C/2 years
In solvent: -80°C/6 months; -20°C/1 month
Regulatory Status This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.
! For research use only, not intended for any clinical use.